Personalised Cancer Medicine Flashcards 2022
Indications determined by the organ of origin
Breast Cancer
Standard
Recommended
Currently not recommended
- Estrogen Receptor
- Progesterone Receptor
- HER2
- Genetic platforms: Mammaprint, Oncotype, Prosigna, or Endopredict*
- BRCA 1 and BRCA 2**
- PDL-1***
- PIK3CA****
- NGS*****
- ESR1
- FGFR1
- AKT1
- PTEN
- Liquid biopsy and circulating cancer cells
* in early luminal breast cancer with high risk of relapsing
** in advanced triple negative or luminal breast cancer
*** in advanced triple negative breast cancer
**** in advanced luminal breast cancer
***** Approved in US as companion diagnostics of a PI3K inhibitor
** in advanced triple negative or luminal breast cancer
*** in advanced triple negative breast cancer
**** in advanced luminal breast cancer
***** Approved in US as companion diagnostics of a PI3K inhibitor
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.
The Recommended category is based on currentrecommendations by EMEA and FDA.
References:
1. Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018 Jul;20(7):815-826. doi: 10.1007/s12094-017-1800-5.
2. Litton JK, Burstein HJ, Turner NC. Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e1-e7. doi: 10.1200/EDBK_237715.
3. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006A.pdf
